Researchers Are Exploring Innovative Nonviral Gene Therapy Delivery Approaches
By Maggie Callahan | Wednesday, November 18, 2026
5 Second Summary
Delivering gene therapy without a virus offers new ways to reach muscle cells. While these approaches could address the limits of viral vectors, questions remain about repeat dosing and whether benefits seen in the lab will translate to people.
Since the advent of gene therapies, which seek to treat a disease by modifying, replacing, or turning off a faulty gene inside the body, scientists have faced a question: How to get the therapy into the right parts of the body?
So far, the most effective answer has been viral vectors.
“Viruses have evolved over many, many millennia to infect cells,” says Angela Lek, PhD, Chief Research Officer at MDA. Researchers essentially take advantage of that ability, removing the disease-causing components of a virus and using the resulting viral vector to carry therapeutic genetic material instead.

Angela Lek, PhD
Viral vectors can carry a working gene, as in currently approved gene replacement therapies, or they can deliver components for other approaches, including experimental gene editing.
So far, the Food and Drug Administration (FDA) has approved three gene therapies for neuromuscular diseases, all of which use an adeno-associated virus (AAV) as the delivery vehicle:
- Onasemnogene abeparvovec-xioi (Zolgensma) for spinal muscular atrophy (SMA)
- Onasemnogene abeparvovec-brve (Itvisma) for SMA
- Delandistrogene moxeparvovec-rokl (Elevidys) for Duchenne muscular dystrophy (DMD)
In each of these therapies, the AAV carries therapeutic genetic material into target cells.
Researchers say that AAVs are very good at this job. But AAVs also come with limitations, which are driving researchers to explore a new, potentially significant approach: nonviral delivery of gene therapy.
The limitations of viral delivery
While AAVs have made gene therapies possible for some neuromuscular diseases, they also have limitations. Some of the main challenges are:
Preexisting immunity can exclude people from treatment.
Some people already have antibodies against certain AAVs from previous exposure to naturally occurring viruses. Depending on the therapy and antibody levels, this can make them ineligible for AAV-based gene therapy.
Treatments are considered one-time doses.
Because they can trigger an immune response, people who receive an AAV-based therapy generally develop antibodies against the viral vector. This can make it difficult to safely and effectively administer the same vector again.
AAVs have been associated with adverse reactions.
The body’s immune response to AAVs can damage liver cells and cause elevated liver enzymes; in severe cases, it may lead to liver failure. AAV-based therapies have also been associated with neurological and cardiac complications, including heart muscle inflammation. These events are uncommon and not well-understood, but they underscore the need for careful dose selection and long-term monitoring.
AAVs cannot carry large genes.
Their limited carrying capacity is particularly important for diseases such as DMD, which is caused by a mutation in the dystrophin gene, which is exceptionally large. The full dystrophin gene would not fit in an AAV. Elevidys, the only approved gene therapy for DMD, uses a shortened version of the gene, called microdystrophin.
New ways to deliver genes
Nonviral approaches don’t use a single method. Rather, the term encompasses a variety of ways to deliver genetic material — including DNA and RNA, as well as gene-editing tools — into cells without a viral vector. Some of these delivery technologies are already used or being explored in other areas of medicine, including cardiology.
Several approaches are being investigated for neuromuscular diseases, including:
Microbubbles and ultrasound
This approach pairs microscopic bubbles made of lipids (fat molecules) with ultrasound technology. The microbubbles are mixed with genetic material and administered intravenously. “You use the ultrasound waves at a specific frequency to attract those microbubbles to the area that you want the genetic material to go,” says Aravindhan Veerapandiyan, MD, a pediatric neurologist at Arkansas Children’s Hospital.
Dr. Veerapandiyan is preparing to be involved in an early-stage DMD clinical trial investigating this delivery method and determining its safety and efficacy in humans. The approach being studied would deliver the full-length dystrophin gene, rather than the shortened gene used in current AAV-based DMD gene therapy.
Lipid nanoparticles (LNPs)
These tiny, fat-based particles can encapsulate genetic material or tools and help carry them into cells. Researchers are making and testing different formulations to improve their ability to reach specific tissues, including skeletal and cardiac muscle. There are currently no approved gene-editing therapies for neuromuscular diseases. By providing a way to carry gene-editing tools into muscle cells, LNPs could help make these types of treatments possible.

Scot Wolfe, PhD
Scot Wolfe, PhD, a professor at UMass Chan Medical School, and his team are engaged in an MDA-funded study of lipid nanoparticles to deliver genome-editing tools for limb-girdle muscular dystrophy type 2G (LGMD2G, also known as LGMDR7). His team is currently testing the approach in mice by injecting the lipid nanoparticles directly into affected skeletal muscle. The tools can then repair a mutation or rewrite a small sequence in the genome.
LNPs may be particularly useful for gene editing because they can limit how long the editing tools remain active in the body. Unlike gene replacement, where long-term production of a needed protein can be beneficial, gene-editing tools only need to be active long enough to make the intended change. If they remain active longer, there is more opportunity for them to cause unintended changes.
“There is enough time for them to go and address the primary mutation that needs to be corrected, but not long enough for them to hang around and potentially overedit and damage the genome,” Dr. Wolfe says.
Antibody-mediated delivery
Another approach uses antibodies, which are proteins made by the immune system to recognize and target specific molecules. They could be used to help carry genetic material into muscle cells.
One company, Myosana, is researching delivering a full-length dystrophin gene by targeting GLUT4, a protein in skeletal and cardiac muscle that naturally moves between the surface and interior of cells. Genetic material is attached to an antibody that recognizes GLUT4, allowing it to essentially hitch a ride into the cell.
Other methods
Other approaches under investigation include:
- Biopolymers, which are naturally derived or biologically compatible molecules that can be engineered to package and protect genetic material and help deliver it into target cells
- Extracellular vesicles, which are naturally occurring particles that cells use to transport materials between cells
- Protein-RNA complexes, which involve a stabilized RNA bound to a genome-editing protein
“There are a lot of different approaches that are being investigated with regard to nonviral delivery, and it’s hard to know what is going to be the superior platform at this time,” Dr. Wolfe says.
What comes next?
As researchers work to ready these approaches for human clinical trials, there are many questions they strive to answer:
Can these treatments reach enough of the right tissues?
Neuromuscular diseases can affect muscles throughout the body. That means researchers need delivery systems that can reach not only skeletal muscle but, depending on the disease, the heart and diaphragm. Dr. Wolfe’s own research on LNPs illustrates the challenge. His team injects LNPs directly into skeletal muscles in mice.
While this approach would be possible to do in humans, Dr. Wolfe says it would be tedious for patients, as injections into many different muscle groups may be required to get the desired effect.
“Skeletal muscle is the largest organ system in the human body with regard to mass, so it’s challenging to get distribution to all skeletal muscle,” he says. “Because of that, we’re working on strategies for systemic delivery, and the hope is it would be an IV delivery over a period of time that would allow these lipid nanoparticles to distribute in the bloodstream and then distribute to skeletal muscle throughout the body.”
Dr. Wolfe says several researchers are working to find a technology that would efficiently deliver a therapy to skeletal muscle throughout the body. “I think it’s something that will happen in the next couple of years because of all of the effort that’s going into it,” he says.
Dr. Lek sees the same challenge across various nonviral approaches. “Getting the nonviral delivery method to specifically hone in on the target tissues that you need remains one of the biggest obstacles,” she says.
Are they safe, and can they be redosed?
Researchers still need to determine appropriate doses and understand how the body responds to different nonviral delivery methods. But the ability to give more than one dose could ultimately be an important advantage. Dr. Wolfe and his team have been able to give repeated LNP doses in mouse models, which allows them to increase the amount of gene editing in muscle tissue.
Researchers will also explore whether people who have already received an AAV therapy can receive a nonviral treatment.
Will the benefits translate to people?
Much of this work remains preclinical — meaning it is being studied in the lab and on animals before it is tested in people — but many companies are developing clinical trials or are very close to doing so.
Overall, this means that progress will take time.
If researchers can overcome the remaining delivery challenges, Dr. Wolfe expects the field to move quickly. “I expect that we’ll see clinical trials get underway en masse for a number of different muscular dystrophies,” he says.
Dr. Lek sees similar potential, particularly once researchers have evidence that these approaches work in people. “Then, I think the field will shift toward these nonviral-based therapies,” she says.
For now, Dr. Veerapandiyan sums up the research community’s outlook simply: “I’m cautiously optimistic.”
Maggie Callahan is a frequent contributor to Quest Magazine.
Different Treatments Need Different Delivery Methods
Every drug needs to reach its intended target to be effective. What a treatment needs to do — and where it needs to go — helps determine how it is delivered into the body.
As an example, let’s look at three spinal muscular atrophy (SMA) treatments that work on different parts of the disease mechanism.
The gene replacement therapy nasemnogene abeparvovec-xioi (Zolgensma) is designed to deliver a working SMN1 gene into cells. It uses an adeno-associated virus (AAV) vector to carry that gene into target cells. Zolgensma is administered via intravenous (IV) infusion into a vein so the vector can travel through the bloodstream to reach cells throughout the body.
Nusinersen (Spinraza) targets RNA, which plays an important role in how genes make proteins. This treatment is an antisense oligonucleotide (ASO) that binds to RNA made from the SMN2 gene and changes how that RNA is processed, allowing the body to produce more functional survival motor neuron (SMN) protein. The drug is injected into the fluid around the spinal cord, which helps carry it to motor neurons it needs to reach.
Risdiplam (Evrysdi) also uses RNA to increase production of SMN protein. It works by changing how the SMN2 gene’s instructions are read so the body can build more of the essential SMN protein. When taken as a liquid by mouth, Evrysdi can cross the blood-brain barrier to be distributed throughout the central nervous system.
For any therapy, an effective delivery method is essential to its success.
Next Steps and Useful Resources
- My Gene Therapy Journey is a Quest Media series about community members’ real experiences with gene therapies — in clinical trials and approved therapies.
- Stay up to date on Quest content! Subscribe to Quest Magazine and Newsletter.
Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.


